4.7 Article

Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders

Journal

BLOOD
Volume 120, Issue 14, Pages 2918-2924

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-03-417758

Keywords

-

Categories

Funding

  1. Public Health Service from National Cancer Institute (NCI) [U24-CA76518]
  2. Public Health Service from National Heart, Lung, and Blood Institute (NHLBI) [U24-CA76518]
  3. Public Health Service from National Institute of Allergy and Infectious Diseases (NIAID) [U24-CA76518]
  4. NHLBI [5U01HL069294]
  5. NCI [5U01HL069294]
  6. Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]
  7. Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
  8. Allos Inc
  9. Amgen Inc
  10. Angioblast
  11. Ariad
  12. Be the Match Foundation
  13. Blue Cross and Blue Shield Association
  14. Buchanan Family Foundation
  15. CaridianBCT
  16. Celgene Corporation
  17. CellGenix GmbH
  18. Children's Leukemia Research Association
  19. Fresenius-Biotech North America Inc
  20. Gamida Cell Teva Joint Venture Ltd
  21. Genentech Inc
  22. Genzyme Corporation
  23. GlaxoSmithKline
  24. HistoGenetics Inc
  25. Kiadis Pharma
  26. Leukemia & Lymphoma Society
  27. Medical College of Wisconsin
  28. Merck Co Inc
  29. Millennium: The Takeda Oncology Co
  30. Milliman USA Inc
  31. Miltenyi Biotec Inc
  32. National Marrow Donor Program
  33. Optum Healthcare Solutions Inc
  34. Osiris Therapeutics Inc
  35. Otsuka America Pharmaceutical Inc
  36. RemedyMD
  37. Sanofi
  38. Seattle Genetics
  39. Sigma-Tau Pharmaceuticals
  40. Soligenix Inc
  41. Stem-Cyte, A Global Cord Blood Therapeutics Co
  42. Stemsoft Software Inc
  43. Swedish Orphan Biovitrum
  44. Tarix Pharmaceuticals
  45. Teva Neuroscience Inc
  46. THERAKOS Inc
  47. Wellpoint Inc

Ask authors/readers for more resources

The importance of human leukocyte antigen (HLA) matching in unrelated donor transplantation for nonmalignant diseases (NMD) has yet to be defined. We analyzed data from 663 unrelated marrow and peripheral blood stem cell transplants performed from 1995 to 2007 for treatment of NMD. Transplantation from a donor mismatched at the HLA-A, -B, -C, or -DRB1, but not -DQB1 or -DPB1, loci was associated with higher mortality in multivariate analyses (P = .002). The hazard ratio for mortality for single (7/8) and double mismatched (6/8) transplants was 1.29 (0.97-1.72; P = .079) and 1.82 (1.30-2.55; P = .0004), respectively, compared with 8/8 matched transplants. HLA mismatches were not associated with acute or chronic GVHD, but were strongly associated with graft failure. After adjustment for other factors, the odds ratio for graft failure for 7/8 and 6/8 (allele and/or antigen) matched pairs compared with 8/8 matched transplants was 2.81 (1.74-4.54; P < .0001) and 2.22 (1.26-3.97; P = .006), respectively. Patients with NMD should receive transplants from allele matched (8/8) donors if possible. Unlike the case with malignancies, HLA mismatching in NMD is associated with graft failure rather than GVHD. (Blood. 2012; 120(14): 2918-2924)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available